RECOMBINA BIOTECH

Transforming the future through biotechnology.

Biotechnology | Vaccines | Proteins | Bacteria

Description

We are a biotechnology company specialized in genetic engineering services and construction of custom recombinant microorganisms.

We take pride in offering innovative biotechnological solutions with applications across a wide range of sectors. Our focus lies in designing microorganisms “à la carte” that present new functionalities, with the final aim of improving existing processes or developing new ones. We are committed to advancing science and technology, especially in the fields of vaccines, biosensors, biomaterials, and therapies for various diseases.

Our highly trained and experienced team utilizes advanced genetic engineering techniques to manipulate and reprogram microorganisms, tailoring them to the needs of each client.
Some of our services include:

• Construction of recombinant microorganisms
We design and build custom microorganisms using advanced genetic engineering techniques. These microorganisms possess new functionalities and capabilities, opening up new possibilities in areas such as applied scientific research, healthcare, the environment, and the agri-food industry.

• Optimization of biotechnological processes
By applying genetic engineering strategies, we identify and modify key components of the system to achieve superior results.

• Development of therapies and vaccines
We specialize in the development of biomedical therapies and vaccines using innovative genetic engineering approaches

• Advisory and consulting services for biotechnological projects
Our team of experts provides specialized advice and consulting services for biotechnological projects.
The technological character of RECOMBINA has been recognized by the Government of Navarra as an innovative technological-based company of Navarra, and by the Spanish Ministry of Science and Innovation with the Innovative SME seal.

Featured proyects

  • In 2023, as a result of a project funded by CDTI (IBEROEKA), RECOMBINA filed the patent “Vaccine System based on Mutant Strains of Salmonella” derived from the INNORAB project. The invention consists of a vaccine platform based on attenuated strains of Salmonella and outer membrane vesicles (OMVs) obtained from these strains. This new technology has been developed with the aim of developing new vaccines based on OMVs with direct application in the fields of human and veterinary health. (read more)

 

The company has also been involved in other exciting projects:

  • INNORAB Project: This project resulted in the development of a patent for a “Vaccine System based on Mutant Strains of Salmonella” aimed at creating a vaccine platform utilizing attenuated strains of Salmonella and outer membrane vesicles (OMVs) for applications in human and veterinary health. (read more)

 

  • AGATA Project (Proyectos Estratégicos I+D 2020-2022): This multidisciplinary project demonstrated the value of genomics in personalized medicine and the development of new cancer therapies, emphasizing the implementation of genomic insights for tailored treatments. (read more)

 

  • DESCARTHeS Project (Proyectos Estratégicos I+D 2019-2021): Aimed at developing CAR-T cell-based therapies for the treatment of hematological and solid tumors, this interdisciplinary project seeks to advance the field of immunotherapy for cancer treatment. (read more)
Abanza